復星醫藥(600196.SH)子公司收到DiaMedica關於終止許可協議的通知
格隆匯8月14日丨復星醫藥(600196.SH)公佈,2018年9月27日,公司控股子公司錦州奧鴻藥業有限責任公司(“奧鴻藥業”)與加拿大DiaMedica Therapeutics, Inc.(“DiaMedica”)簽訂《License and Collaboration Agreement》,奧鴻藥業獲DiaMedica許可:(1)在區域內(即中國)及領域內(即治療人急性缺血性腦卒中,下同)獨家進口註冊、臨牀開發和商業化重組人組織激肽釋放酶1(即rh-KLK1)DM199製劑(以下簡稱“該產品”);(2)在區域內合理的再授權及委託分包的權利。
由於中國境內的臨牀方案有待進一步論證,該產品於2019年7月1日前未能獲得國家藥品監督管理局臨牀試驗批准、奧鴻藥業也因此無義務支付首期研發里程碑付款。根據約定,該情形下,DiaMedica有權終止《許可協議》,且應當給予雙方30天的磋商期;若磋商期滿且雙方未就有關安排達成一致的,雙方均有權發出終止《許可協議》的書面通知。
鑑於該產品開發現狀,經上述約定程序,雙方未能就協議後續履行的有關安排達成一致。北京時間2019年8月13日,奧鴻藥業收到DiaMedica關於終止《許可協議》的通知:《許可協議》於奧鴻藥業收到該等通知時即刻終止。
截至2019年7月,集團現階段針對該產品累計研發投入為人民幣約942萬元(未經審計,包括奧鴻藥業已向DiaMedica支付50萬美元的許可費)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.